COGNITION THERAPEUTICS INC (CGTX)

Company Profile

Cognition Therapeutics, Inc. is a clinical stage neuroscience company, which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 25 full-time employees. The company went IPO on 2021-10-08. The firm is investigating its lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy bodies and dry age-related macular degeneration (dry AMD). Its lead product candidate, CT1812, is an investigational orally delivered, small molecule modulator that penetrates the blood-brain and blood-retina barriers and binds selectively to the sigma-2 receptor (S2R) complex; and through its modulation of S2R restores normal function of synapses, as well as critical cellular processes such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling, lipid membrane-bound protein trafficking and receptor stabilization at the cell surface. The company is developing other product candidates in the area of synucleinopathies.

Company Info

COGNITION THERAPEUTICS INC

Suite 261, 2403 Sidney Street

Pittsburgh PENNSYLVANIA

P: 14127701621

Employees: 27

Website: https://cogrx.com/